Market Capitalization (Millions $) |
14 |
Shares
Outstanding (Millions) |
730 |
Employees |
- |
Revenues (TTM) (Millions $) |
14 |
Net Income (TTM) (Millions $) |
44 |
Cash Flow (TTM) (Millions $) |
-9 |
Capital Exp. (TTM) (Millions $) |
0 |
Evofem Biosciences Inc
Evofem Biosciences Inc is a biopharmaceutical company that focuses on the development and commercialization of innovative products to address unmet needs in women's sexual and reproductive health. The company is committed to empowering women by providing them with safe and effective options for contraception and prevention of sexually transmitted infections.
Evofem's lead product candidate is Phexxi, a non-hormonal contraceptive gel that is designed to be bioadhesive and pH-regulating. Phexxi is intended to be used by women immediately before sexual intercourse to prevent pregnancy.
In addition to Phexxi, Evofem is also working on developing other novel product candidates for contraceptive and women's health indications. The company is dedicated to advancing scientific research and leveraging technology to improve the lives of women worldwide.
Evofem Biosciences Inc aims to address the gaps and limitations in current options available to women for contraception and sexual health. Through its innovative approach and commitment to women's health, the company strives to make a positive impact on women's lives and improve their overall well-being.
Company Address: 7770 Regents Road San Diego 92122 CA
Company Phone Number: 550-1900 Stock Exchange / Ticker: EVFM
EVFM is expected to report next financial results on April 26, 2024. |
|
|